Justice Department Ends Bristol-Myers Squibb FCPA Probe
The Department of Justice has ended its investigation into allegations that pharmaceutical giant Bristol-Myers Squibb violated the Foreign Corrupt Practices Act. Earlier this month the company reached a $14 million settlement with the SEC for FCPA violations relating to certain sales and marketing practices in China. More inside.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleGavin Proudley, SVP Risk & Compliance at Dow Jones, on compliance challenges from divergent rules and geopolitics
Diverging global rules, sanctions, and tariffs being “weaponized,” and more have made compliance complex even before the U.S. strikes on Iran. We asked Gavin Proudley, SVP Risk & Compliance at Dow Jones, what this means for compliance managers and how they can stay ahead of shifting geopolitics and tighter ...
-
ArticleDOJ makes good on corporate-friendly enforcement policy with Balt resolution
The ink was barely dry on the U.S. Department of Justice’s new corporate enforcement policy (CEP) when the agency announced it would not prosecute Balt SAS for alleged bribery violations.
-
ArticleLong-running corruption scandal adds €25.8M fine to billions already paid globally
The Netherlands Public Prosecution Office has fined a company linked to a U.S.-sanctioned Israeli businessman €25.8 million ($29.9 million) for bribing officials in the Congo. The case began in 2018 and relates to bribes paid in 2010-2011, demonstrating the slow and complex process often involved in such investigations.